A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
NCT02399137
Completed
The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients with high serum levels of free IGF-1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2018
Locations: Banner MD Anderson Cancer Ctr., Gilbert, Arizona +65 locations
Conditions: Pancreatic Cancer
Register for Updates
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
NCT00915018
Completed
This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for erbB-2-positive locally recurrent or metastatic breast cancer. The study will compare the effectiveness of each regimen in shrinking tumors and extending the lives of women with erbB-2 (HER2) positive breast cancer. The study will also compare the safety of the two regim... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/25/2018
Locations: Ventura County Hematology-Oncology Specialists, Oxnard, California +194 locations
Conditions: Breast Cancer
Register for Updates
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
NCT01852292
Terminated
Phase II Study of efficacy and safety of buparlisib (BKM120) plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic Head and Neck cancer previously pre-treated with a platinum therapy.The primary endpoint was PFS and the key secondary endpoint was Overall Survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2018
Locations: Highlands Oncology Group, Fayetteville, Arkansas +57 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
NCT01006252
Terminated
The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2018
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +121 locations
Conditions: Melanoma
Register for Updates
F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
NCT02054884
Terminated
There is no standard treatment for Merkel cell carcinoma(MCC), as no randomized trials have been conducted to establish standard of care. Despite a sizable number of objective responses induced by combination cyototoxic chemotherapy, a prolongation of patients overall survival has never been demonstrated. This open-label, randomized, double-arm, multi-centre, phase II study of F16IL2 in combination with paclitaxel versus paclitaxel monotherapy, proposes to test the therapeutic efficacy of F16IL... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/15/2018
Locations: Medical University Hospital, Graz, Not set +7 locations
Conditions: Merkel Cell Carcinoma
Register for Updates
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
NCT00866528
Completed
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2017
Locations: GSK Investigational Site, Chicago, Illinois +3 locations
Conditions: Lung Cancer, Non-Small Cell
Register for Updates
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
NCT01015118
Completed
The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/03/2017
Locations: 1199.15.10113 Boehringer Ingelheim Investigational Site, Tucson, Arizona +280 locations
Conditions: Ovarian Neoplasms, Peritoneal Neoplasms
Register for Updates
A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
NCT00937560
Completed
This single arm study evaluated the efficacy and safety of first-line chemotherapy with carboplatin and dose-dense weekly paclitaxel plus bevacizumab (Avastin) in participants with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants received 6-8 3-week cycles of treatment with bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m\^2 iv on days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve (AUC) of 6 on day 1 of... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/05/2017
Locations: Hospital Amaral Carvalho, Jau, SP +54 locations
Conditions: Ovarian Cancer
Register for Updates
Dose-finding Study in Platinum-Resistant Ovarian Cancer
NCT01653912
Completed
* Dose-finding study of GSK2110183 administered in combination with carboplatin and paclitaxel to any subject with recurrent ovarian cancer. * Safety and efficacy study of GSK2110183 administered in combination with carboplatin and paclitaxel to subjects with platinum-resistant ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/30/2017
Locations: Royal Brisbane and Women's Hospital, Herston, Queensland +9 locations
Conditions: Recurrent Platinum-resistant Ovarian Cancer
Register for Updates
A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer
NCT01094184
Completed
This open-label, multi-center study will evaluate the safety, tolerability and effect of bevacizumab (Avastin) in combination with taxane (paclitaxel/ docetaxel) monotherapy on disease progression, survival time and Karnofsky performance status in female participants with estrogen-, progesterone- and human epidermal growth factor receptor 2 (HER2)-negative (triple-negative) breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/25/2017
Locations: Not set, Bangor, Not set +9 locations
Conditions: Breast Cancer
Register for Updates
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
NCT00111787
Completed
This Study was designed to determine how effective and safe a new investigational drug, lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed inflammatory breast cancer. Tumor tissue collected pre-treatment, following 14 days of treatment and at the time of surgical resection will be examined for pathologic response and biologic activity by IHC (immunohistochemistry) within the tumor. Treatment will consist of 14 days of lapatinib monotherapy followed by 12 weeks... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2017
Locations: GSK Investigational Site, Miami, Florida +24 locations
Conditions: Neoplasms, Breast
Register for Updates
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
NCT01493843
Completed
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2017
Locations: Alabama Oncology, Birmingham, Alabama +119 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates